KASID
Search
- Page Path
- HOME > Search
Original Article
- IBD
- Effects of COVID-19 vaccines on patient-reported outcomes in patients with inflammatory bowel disease: a multicenter survey study in Korea
- Jung Hyun Ji, Seung Hwan Shin, Yong Eun Park, Jihye Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim, Sang-Bum Kang, Sang Hyoung Park, Soo Jung Park, IBD Research Group of the Korean Association for the Study of Intestinal Diseases (KASID)
- Intest Res 2024;22(3):336-350. Published online March 26, 2024
- DOI: https://doi.org/10.5217/ir.2023.00077
-
Abstract
PDF
PubReader
ePub - Background/Aims
The impact of vaccination on inflammatory bowel disease (IBD) patients is still unknown, and no studies have assessed the changes in patient-reported outcomes (PROs) after vaccination in patients with IBD. Therefore, in this study, we investigated the impact of vaccines on the PROs of patients with IBD.
Methods
We conducted a questionnaire survey of patients with IBD who visited outpatient clinics at 4 specialized IBD clinics of referral university hospitals from April 2022 to June 2022. A total of 309 IBD patients were included in the study. Patient information was collected from a questionnaire and their medical records, including laboratory findings, were reviewed retrospectively. Risk factors associated with an increase in PROs after COVID-19 vaccination were analyzed using logistic regression analyses. In addition, we assessed whether there were differences in variables by vaccine order using the linear mixed model.
Results
In multivariate analysis, young age ( < 40 years) and ulcerative colitis (UC) were found to be independent risk factors for aggravation of PROs in patients with IBD. In all patients, platelet count significantly increased with continued vaccination in multiple pairwise comparisons. In UC patients, PROs such as the short health scale, UC-abdominal signs and symptoms, and UC-bowel signs and symptoms were aggravated significantly with continued vaccination. There was no significant increase in the variables of patients with Crohn’s disease.
Conclusions
Therefore, there may be a need to counsel patients with IBD younger than 40 years of age, and patients with UC before they receive COVID-19 vaccinations.
- 1,973 View
- 179 Download
Editorials
- IBD
- Which biomarkers best reflect the degree of inflammation in Crohn’s disease?
- Jihye Park
- Intest Res 2024;22(1):1-2. Published online January 29, 2024
- DOI: https://doi.org/10.5217/ir.2023.00161
- 2,595 View
- 137 Download
- IBD
- How have treatment patterns for patients with inflammatory bowel disease changed in Asian countries?
- Jihye Park
- Intest Res 2023;21(3):275-276. Published online July 27, 2023
- DOI: https://doi.org/10.5217/ir.2023.00061
- 1,594 View
- 88 Download
Original Article
- Colorectal neoplasia
- Clinical characteristics and risk factors related to polyposis recurrence and advanced neoplasm development among patients with non-hereditary colorectal polyposis
- Jihun Jang, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim
- Intest Res 2023;21(4):510-517. Published online May 31, 2023
- DOI: https://doi.org/10.5217/ir.2022.00139
-
Abstract
PDFPubReaderePub
- Background/Aims
Patients with more than 10 cumulative polyps might involve a greater genetic risk of colorectal neoplasia development. However, few studies have investigated the risk factors of polyposis recurrence and development of advanced neoplasms among patients with non-hereditary colorectal polyposis.
Methods
This study included patients (n=855) with 10 or more cumulative polyps diagnosed at Severance Hospital from January 2012 to September 2021. Patients with known genetic mutations related to polyposis, known hereditary polyposis syndromes, insufficient information, total colectomy, and less than 3 years of follow-up were excluded. Finally, 169 patients were included for analysis. We collected clinical data, including colonoscopy surveillance results, and performed Cox regression analyses of risk factors for polyposis recurrence and advanced neoplasm development.
Results
The 169 patients were predominantly male (84.02%), with a mean age of 64.19±9.92 years. The mean number of adenomas on index colonoscopy was 15.33±8.47. Multivariable analysis revealed history of cancer except colon cancer (hazard ratio [HR], 2.23; 95% confidence interval [CI], 1.23–4.01), current smoking (HR, 2.39; 95% CI, 1.17–4.87), and detection of many polyps (≥15) on index colonoscopy (HR, 2.05; 95% CI, 1.21–3.50) were significant risk factors for recurrence of polyposis. We found no statistically significant risk factors for advanced neoplasm development during surveillance among our cohort.
Conclusions
The presence of many polyps (≥15) on index colonoscopy, history of cancer except colon cancer, and current smoking state were significant risk factors for polyposis recurrence among patients with non-hereditary colorectal polyposis. -
Citations
Citations to this article as recorded by
- Screening and surveillance for hereditary colorectal cancer
Hee Man Kim, Tae Il Kim
Intestinal Research.2024; 22(2): 119. CrossRef
- Screening and surveillance for hereditary colorectal cancer
- 2,156 View
- 303 Download
- 1 Web of Science
- 1 Crossref
Statement
- Endoscopy
- Use of device-assisted enteroscopy in small bowel disease: an expert consensus statement by the Korean Association for the Study of Intestinal Diseases
- Han Hee Lee, Jin Su Kim, Hyeon Jeong Goong, Shin Hee Lee, Eun Hye Oh, Jihye Park, Min Cheol Kim, Kwangwoo Nam, Young Joo Yang, Tae Jun Kim, Seung-Joo Nam, Hee Seok Moon, Jae Hyun Kim, Duk Hwan Kim, Seong-Eun Kim, Seong Ran Jeon, Seung-Jae Myung, The Small Intestine Research Group of the Korean Association for the Study of Intestinal Diseases (KASID)
- Intest Res 2023;21(1):3-19. Published online January 31, 2023
- DOI: https://doi.org/10.5217/ir.2022.00108
-
Abstract
PDFPubReaderePub
- The introduction of device-assisted enteroscopy (DAE) in the beginning of 21st century has revolutionized the diagnosis and treatment of diseases of the small intestine. In contrast to capsule endoscopy, the other main diagnostic modality of the small bowel diseases, DAE has the unique advantages of observing the region of interest in detail and enabling tissue acquisition and therapeutic intervention. As DAE becomes an essential procedure in daily clinical practice, there is an increasing need for correct guidelines on when and how to perform it and what technical factors should be considered. In response to these needs, the Korean Association for the Study of Intestinal Diseases developed an expert consensus statement on the performance of DAE by reviewing the current evidence. This expert consensus statement particularly focuses on the indications, choice of insertion route, therapeutic intervention, complications, and relevant technical points.
-
Citations
Citations to this article as recorded by- From Data to Insights: How Is AI Revolutionizing Small-Bowel Endoscopy?
Joana Mota, Maria João Almeida, Francisco Mendes, Miguel Martins, Tiago Ribeiro, João Afonso, Pedro Cardoso, Helder Cardoso, Patrícia Andrade, João Ferreira, Miguel Mascarenhas, Guilherme Macedo
Diagnostics.2024; 14(3): 291. CrossRef - Role of Device-Assisted Enteroscopy in Crohn’s Disease
Giulia Catassi, Clelia Marmo, Antonio Gasbarrini, Maria Elena Riccioni
Journal of Clinical Medicine.2024; 13(13): 3919. CrossRef - Discordance Rate and Risk Factor of Other Diagnostic Modalities for Small Bowel Tumors Detected by Device-Assisted Enteroscopy: A Korean Association for the Study of Intestinal Disease (KASID) Multicenter Study
Jihye Park, Jin Su Kim, Joo Hye Song, Kwangwoo Nam, Seong-Eun Kim, Eui Sun Jeong, Jae Hyun Kim, Seong Ran Jeon
Gut and Liver.2024; 18(4): 686. CrossRef
- From Data to Insights: How Is AI Revolutionizing Small-Bowel Endoscopy?
- 6,338 View
- 205 Download
- 3 Crossref
Brief Communication
- IBD
- Anti-inflammatory properties of butyrate-producing atypical Escherichia coli in a murine colitis model
- Ji Hyung Kim, Jee In Yoo, Hyun Woo Ma, I Seul Park, Mijeong Son, Yoojin Shin, Ki Beom Kim, Seung Won Kim, Si Jae Park, Jihye Park
- Intest Res 2023;21(2):266-269. Published online November 14, 2022
- DOI: https://doi.org/10.5217/ir.2022.00112
Supplementary Material- 2,585 View
- 359 Download
Editorial
- IBD
- Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?
- Jihye Park
- Intest Res 2022;20(1):1-2. Published online January 26, 2022
- DOI: https://doi.org/10.5217/ir.2021.00170
-
PDFPubReaderePub
-
Citations
Citations to this article as recorded by- Vaccination strategies for Korean patients with inflammatory bowel disease
Yoo Jin Lee, Eun Soo Kim
The Korean Journal of Internal Medicine.2022; 37(5): 920. CrossRef
- Vaccination strategies for Korean patients with inflammatory bowel disease
- 3,239 View
- 194 Download
- 1 Web of Science
- 1 Crossref
Brief Communcation
- IBD
- Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model
- Jihye Park, Da Hye Kim, Soochan Kim, Hyun Woo Ma, I Seul Park, Mijeong Son, Ji Hyung Kim, Yoojin Shin, Seung Won Kim, Jae Hee Cheon
- Intest Res 2021;19(4):478-481. Published online October 26, 2021
- DOI: https://doi.org/10.5217/ir.2021.00121
-
PDFPubReaderePub
-
Citations
Citations to this article as recorded by-
Expectations for employing
Escherichia coli
Nissle 1917 in food science and nutrition
Miaomiao Hu, Tao Zhang, Ming Miao, Kewen Li, Qingmin Luan, Guilian Sun
Critical Reviews in Food Science and Nutrition.2024; : 1. CrossRef - Potential of using an engineered indole lactic acid producing Escherichia coli Nissle 1917 in a murine model of colitis
Chrysoula Dimopoulou, Priscila Regina Guerra, Martin Steen Mortensen, Katja Ann Kristensen, Mikael Pedersen, Martin Iain Bahl, Morten Alexander Otto Sommer, Tine Rask Licht, Martin Frederik Laursen
Scientific Reports.2024;[Epub] CrossRef - Priority order of neonatal colonization by a probiotic or pathogenic Escherichia coli strain dictates the host response to experimental colitis
Tomas Hudcovic, Petra Petr Hermanova, Hana Kozakova, Oldrich Benada, Olga Kofronova, Martin Schwarzer, Dagmar Srutkova
Frontiers in Microbiology.2024;[Epub] CrossRef - Anti-inflammatory properties of butyrate-producing atypical Escherichia coli in a murine colitis model
Ji Hyung Kim, Jee In Yoo, Hyun Woo Ma, I Seul Park, Mijeong Son, Yoojin Shin, Ki Beom Kim, Seung Won Kim, Si Jae Park, Jihye Park
Intestinal Research.2023; 21(2): 266. CrossRef - Microbial Modulation in Inflammatory Bowel Diseases
Jongwook Yu, Jae Hee Cheon
Immune Network.2022;[Epub] CrossRef
-
Expectations for employing
Escherichia coli
Nissle 1917 in food science and nutrition
- 5,035 View
- 120 Download
- 5 Web of Science
- 5 Crossref
Brief Communication
- Miscellaneous
- Efficacy and tolerability of methotrexate therapy for refractory intestinal Behçet's disease: a single center experience
- Jihye Park, Jae Hee Cheon, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim
- Intest Res 2018;16(2):315-318. Published online April 30, 2018
- DOI: https://doi.org/10.5217/ir.2018.16.2.315
-
PDFPubReaderePub
-
Citations
Citations to this article as recorded by- Behçet's syndrome
Giacomo Emmi, Alessandra Bettiol, Gülen Hatemi, Domenico Prisco
The Lancet.2024; 403(10431): 1093. CrossRef - Current pharmacological solutions for Behçet’s syndrome
Yesim Ozguler, Sinem Nihal Esatoglu, Gulen Hatemi
Expert Opinion on Pharmacotherapy.2023; 24(2): 221. CrossRef - Treatment Options in Pediatric Behçet’s Disease
Teresa Giani, Angela Flavia Luppino, Giovanna Ferrara
Pediatric Drugs.2023; 25(2): 165. CrossRef - Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
Jae Hee Cheon
Journal of Rheumatic Diseases.2021; 28(1): 4. CrossRef - Long-term outcome and predictors of remission in Behçet’s disease in daily practice
Aida Malek Mahdavi, Alireza Khabbazi, Mehrzad Hajialilo
Modern Rheumatology.2021; 31(6): 1148. CrossRef - Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice
Da Hye Kim, Soochan Kim, Jae Bum Ahn, Jae Hyeon Kim, Hyun Woo Ma, Dong Hyuk Seo, Xiumei Che, Ki Cheong Park, Jeong Yong Jeon, Sang Yong Kim, Han Cheol Lee, Jae-Young Lee, Tae Il Kim, Won Ho Kim, Seung Won Kim, Jae Hee Cheon
International Journal of Medical Microbiology.2020; 310(2): 151391. CrossRef - Successful combination therapy using adalimumab and 5-aminosalicylic acid for a resistant case of intestinal Behçet’s disease
H. J. Kim, K.‑t. Kim, S.-G. Lee, Y. Kim
Zeitschrift für Rheumatologie.2020; 79(7): 702. CrossRef - Safety of systemic treatments for Behçet’s syndrome
Giuseppe Lopalco, Donato Rigante, Antonio Lopalco, Giacomo Emmi, Vincenzo Venerito, Antonio Vitale, Giovanna Capozio, Nunzio Denora, Luca Cantarini, Florenzo Iannone
Expert Opinion on Drug Safety.2020; 19(10): 1269. CrossRef - Update on the treatment of Behçet’s syndrome
Sinem Nihal Esatoglu, Gulen Hatemi
Internal and Emergency Medicine.2019; 14(5): 661. CrossRef
- Behçet's syndrome
- 5,098 View
- 68 Download
- 8 Web of Science
- 9 Crossref
Editorial
- Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?
- Jihye Park, Jae Hee Cheon
- Intest Res 2017;15(3):263-265. Published online June 12, 2017
- DOI: https://doi.org/10.5217/ir.2017.15.3.263
- 4,500 View
- 44 Download
- 2 Web of Science
- 2 Crossref
First
Prev
